Chapter 1

Introduction

1.1 Background:
MD. Moniruzzaman, Lecturer of Bachelor of Business Administration, BUBT, has suggested us to prepare and assign a report about a particular topic that is Environmental orces !nfluences " #harmaceutical !ndustr$ %&peciall$ focus on ' Economic orces( )hich should be relevant to our practical *no)ledge )ith the course of +Business Environment,. &o, )e have decided to prepare our report on +Environmental orces !nfluences " #harmaceutical !ndustr$ %&peciall$ focus on ' Economic orces(, as our topic.

1.2 Significance / Justification:

-ur research report is on the Environmental orces !nfluences " #harmaceutical !ndustr$ %&peciall$ focus on ' Economic orces(. There are three important ob.ectives for )hich )e have made our research. The$ are as follo)s/ irst, )e collected all the information about pharmaceutical industr$ in Bangladesh including three ma.or pharmaceutical companies in our countr$. &econd, )e had made anal$sis of all the gathered information and based on the anal$sis )e have prepared 0uestionnaire, graphical presentation and samples etc, to ma*e the report effective and meaningful. Last of all )e have tried to include some suggestions to improve the pharmaceutical industr$ including economic forces of the industr$.

1.4 Scope of the Report:

&ince )e )ere assigned to prepare a research paper on pharmaceutical industr$ in Bangladesh, )e get the opportunit$ to gain *no)ledge of different part of the industr$. 1e have made our anal$sis on three pharmaceutical companies in our countr$ such as Be2imco, A3!, and &45 . rom the anal$sis )e hope that )e )ill be capable of providing further information in the future. The scope or span of this report is to highlight the overall performance of #harmaceutical industr$ of Bangladesh )ith related sub.ect matter.

1.3 Objecti e of the Report:

1.3.1. Broad Objective:

The ob.ective of this report is to dra) importance upon ho) environmental forces influences pharmaceutical industries in Bangladesh speciall$ focus on economic force for the partial fulfillment of our course.

1.3.2. Specific Objective:

The secondar$ ob.ective of preparing this report is to investigate about the resemblance and differences bet)een our theoretical and practical *no)ledge. Also the ob.ective of this report is to build up our *no)ledge about pharmaceutical industries in Bangladesh. 7ot onl$ that, the ob.ective of preparing this report is to investigate the economic forces and their environmental forces )hich influences this industr$.

1.! "ethodo#og$:
Throughout the report, )e )ill use different t$pe of research method to find out proper and correct information and also provide a good report. or preparing this report )e )ill basicall$ use our e2perience from three different pharmaceutical companies. And )e )ill also use some official documents provided b$ the emplo$ees of these companies. or adding more value to this report )e )ill use some boo*s or lecture specialized on the pharmaceutical industr$.

1.5.1. Type of research: The report )ould be based on an e2plorator$ research paper. 8ere )e )ould be discussing the pharmaceutical industr$ and its economic forces )hich influences the industr$ and criticall$ anal$ze the three pharmaceutical industries to ma*e the research a standard one.

1.5.2. Sources of data: 1.5.2.1. Primary data: -bservation of activities of the pharmaceutical companies. ruitful conversation )ith the emplo$ees of the pharmaceutical companies. Discussion )ith the consumers about the products of these pharmaceutical companies.

1.5.2.2. Secondary data: Annual reports of pharmaceutical companies. :arious documents from the three ma.or companies. Different )ebsites. !nternal ;ecords of the pharmaceutical companies. Brochures of these companies. -ther published documents about pharmaceutical industr$ of Bangladesh.

1.5.3. Data collection procedure: The data )ere collected both from primary and secondary sources. 1e have collected all necessar$ information b$ reaching to the pharmaceutical companies such as Be2imco, A3! and &45 . B$ the direct discussion )ith the officials of these pharmaceutical companies < consumers and from different boo*s, statements, annual report < other reports related )ith our topic, )e have collected this information,s to prepare our report.

1.5.4. Questionnaire: To ma*e the research an effective one )e have prepared a 0uestionnaire )hich )as provided to the both emplo$ees < customers. And the 0uestionnaire is attached to the anne2ure of our report.

1.5.5. Sampling plan:

1.5.5.1. Population: To ma*e the surve$, )e have served a 0uestionnaire to the emplo$ees < customers of the pharmaceutical industr$, )ho )ere the primar$ sources of our report. The$ have trul$ )ritten do)n the ans)ers of the 0uestions of the 0uestionnaire. Based on the ans)ers of the 0uestionnaire, )e have anal$zed the data to prepare our report.

1.5.5.2. Sample elements/units: -ur sample elements )ere different boo*s, statements, annual report < other reports related )ith our topic, )e have collected this information,s to prepare our report. 1.5.5.3. Sample frame: Mr. M nis !d Do"la Mr. rif Do"la Mrs. $a%ma Do"la Mr. &aliur 'ahman (huiyan )(* Mr. Md. +umayun ,a-ir Mr. .olam Mainuddin Ms. Shusmita nis Salam Ms. Sheema -ed 'ahman Mr. &a%ed Salam Mr. &aliur 'ahman #hairman Managing Director Director Director Director Director Director Director Director Director

Ms. !masa Tahmina Trisha Dr. Mostofa Sa"/at 0mran Dr. 1.+. nsarey Mr. Syed lamgir Mr. M. Mohi-u2 3aman Mr. Muallem . #houdhury Mr. sif 04-al

3ustomer 3ustomer E2ecutive Director, Agribusinesses E2ecutive Director, 3onsumer Brands 3hief -perating -fficer, #harmaceuticals E2ecutive Director, inance and #lanning 3hief -perating -fficer, 3orporate

>

Mr. To"fi4ur 'ahman Mr. 5riyatosh Datta Mr. 5radip ,ar #ho"dhury Ms. Sheema -ed 'ahman Mr. -dus Sade4ue Mr. 0mam hmed 0stia/ Mr. limul 'a%iMr. $afees hmed Mr. Tam2idul lam Mr. -dullah6 l6Maruf Mr. +assan 'ussel Mr. S"adipto lam Mr. +asnat ,arim Sai/at

3ommunications Director, Business Development Director, ?ualit$ Assurance inancial 3ontroller Director, 3orporate Affairs Director, Mar*eting < &ales @eneral Manager, -perations 3ustomer 3ustomer 3ustomer 3ustomer 3ustomer 3ustomer 3ustomer

1.5.5.4. Sampling procedure: 1e )ere able to complete the sampling procedure b$ ta*ing the help of non"probabilit$ convenience procedure to develop the sample plan. 1.5.5.5. Sample size: The sample size of the report is 9A. 1e have made our surve$ to 9A patients of the healthcare organization.

1.5.7. Data analysis 8 reporting: 1hile preparing this report, some problem ma$ be posted during the process. Due to some limitations there can be some erroneous results. Although )e tr$ our level best to eliminate errors, unfortunatel$, )e faced some limitations )hile )or*ing on this report due to lac* of e2perience and *no)ledge. 1e also faced some limitations about time and )ord. 1e haven,t had enough time to prepare this report. There )ere )ord limitations in the report. &o, )e could not state briefl$ about the report.

1.6 %i&itations:
-n the )a$ of our stud$, )e have faced the follo)ing problems, )hich ma$ be termed as the limitations of the stud$. These are/ Short time period: Due to the time limit, the scope and dimension of the stud$ has been curtailed. 1e )ere no given ade0uate time to prepare such as in depth stud$. 0nade4uate data: To understand the facts about the stud$ in a realistic )a$ and more clearl$ the 0uantitative e2pression of information, necessar$ data is re0uired. But it )as ver$ difficult for us to collect the secondar$ data in all area of the stud$. 9ac/ of 'ecord: &ufficient boo*s publications, facts and figures are not available. !f these limitations )ere not been there, the report )ould have more useful and attractive. 5oor 9i-rary 1acility: The librar$ of our universit$ is not )ell ornamented. There are limited collections of pharmaceutical industr$ < compan$ related boo*s, .ournals, magazines, papers, case studies etc. 9ac/ of *:perience: E2perience ma*es a man efficient. But )e have no proper e2perience to do this *ind of report. That,s )h$ ine2perience creates obstacle to follo) the s$stematic and logical research methodolog$.

Chapter 2

O !" I!# O$ %&! 'O(P)*+

2.1 ,ac-ground:
!3! #lc of U4 had a pharmaceutical business in Bangladesh. !n DEE6 the business )as divested to management and the name of the 3ompan$ changed to Advanced 3hemical !ndustries %A3!( Limited. A3! inherited the rich !3! culture of product 0ualit$, customer service and social responsibilit$ and continues to nurture. A3! is the first compan$ in Bangladesh to obtain certification of !&- EAAD ?ualit$ Management &$stem in DEE>. A3! is also the first 3ompan$ in Bangladesh to get certification of !&- D=AAD Environmental Management &$stem in 6AAA. A3!

emplo$ees are proud of their )or* culture, business ethics and environmental consciousness. A3! values are embodied in its mission and vision statements. A3! 0ualit$ and environmental concerns are clearl$ stated through declared policies. 1hat )as primaril$ a #harmaceutical business in DEE6 )ith a turnover of T*.FA million )ith stagnant gro)th, the ne) management brought about fundamental changes in policies and has in $ear 6AA9 gro)n to over T*. 69AA million in turnover through diversified business interest including personal care products, food products, animal health, agrochemicals and seeds in addition to gaining a strong position in #harmaceuticals.

6.D.6 #ompany Mission A3!,s mission is to enrich the 0ualit$ of life of people through responsible application of *no)ledge, s*ills and technolog$. A3! is committed to the pursuit of e2cellence through )orld"class products, innovative processes and empo)ered emplo$ees to provide the highest level of satisfaction to its customers.

6.D.9 #ompany ;ision To realize the mission A3! )ill Endeavour to attain a position of leadership in each categor$ of its businesses. Attain a high level of productivit$ in all its operations through effective and efficient use of resources, adoption of appropriate technolog$ and alignment )ith our core competencies. Develop its emplo$ees b$ encouraging empo)erment and re)arding innovation. E

 #romote an environment for learning and personal gro)th of its emplo$ees. #rovide products and services of high and consistent 0ualit$, ensuring value for mone$ to its customers. #rovide products and services of high and consistent 0ualit$, ensuring value for mone$ to its customers. Establish harmonious relationship )ith the communit$ and promote greater environmental responsibilit$ )ithin its sphere of influence. 6.D.9 .) 9 A3! Ltd is a leading manufacturer of pharmaceutical formulations and Active

#harmaceutical !ngredients %A#!s( in Bangladesh. The compan$ is the largest e2porter of pharmaceuticals in the countr$ and its state"of"the"art manufacturing facilities are certified b$ global regulator$ bodies of Australia, @ulf nations, Brazil, among others. The compan$ is consistentl$ building upon its portfolio and currentl$ producing more than =AA products in different dosage forms covering broader therapeutic categories )hich include antibiotics, antih$pertensives, antidiabetics, antireretrovirals, anti asthma inhalers etc, among man$ others.

1ith decades of contract manufacturing e2perience )ith global M73s, s*illed manpo)er and proven formulation capabilities, the compan$ has been building a visible and gro)ing presence across the continents offering high 0ualit$ generics at the most affordable cost.

Ensuring access to 0ualit$ medicines is the po)erful aspiration that motivates more than 9AAA emplo$ees of the organization, and each of them is guided b$ the same moral and social responsibilities the compan$ values most. +uman 'esources:

DA

The pool of human resources of the compan$ )ill be developed to their full potential and harnessed through regular training and their participation in see*ing continuous improvement of )or* methods. The management of A3! commits itself to 0ualit$ as the prime consideration in all its business decisions. All emplo$ees of A3! must follo) documented procedures to ensure compliance )ith 0ualit$ standards. The management of A3!, a competent team of professionals, thus operates )ith a progressive attitude to provide effective solutions to satisf$ the customers, needs, through its products and services of uncompromising 0ualit$. This highl$ s*illed team is dedicated in producing products )ith consistent 0ualit$ under clearl$ defined &tandard -perating #rocedures %&-#( in compliance )ith the procedures and instructions of !&- EAAD 0ualit$ s$stem. 6.D.> ; 9!*S ?ualit$ 3ustomer ocus airness

Transparenc$ 3ontinuous !mprovement

6.D.B D0ST'0(!T0)$ $*T&)', The compan$ maintains strategicall$ located sales centers in nineteen different locations across the countr$. !t has developed an advanced distribution s$stem through its s*illed

DD

and trained manpo)er and a large fleet over eight$ vehicles. The distribution s$stem is full$ e0uipped for handling continuing volume of diverse range of products from the various businesses. The compan$Gs distribution centers are highl$ streamlined, computerized and automated. 1e are capable of maintaining a cold chain for some specialized range of products such as vaccines and insulin. The combination of this advanced function and multidimensional capabilities made it possible to handle hundreds of products efficientl$.

6.D.C (!S0$*SS !$0T !n 6AA=, A3! #harmaceuticals ran*ed DDth in the Bangladesh #harmaceuticals !ndustr$. !t provides the mar*et )ith a )ide selection of drugs across all ma.or therapeutic classes, and also offers some specialt$ medicines. A3! #harmaceutical represents AstraHeneca, Eli Lil$ and U3B in Bangladesh. A3! 3rop 3are and #ublic 8ealth Division is holding the leadership position in the industr$I Animal 8ealth has e2perienced one of the highest gro)th rates in this sector. A3! Agribusiness has partnerships )ith several international conglomerates including 3eva &anthe Animale, !nvesa, U3B, !sagro Asia and Borregaard Taicang 3hemicals 3o. Ltd. A3! 3onsumer Brands is a leading ast Moving 3onsumer @oods % M3@( compan$ in Bangladesh. !n the li0uid antiseptic and mos0uito repellant categories, this division is a ver$ strong mar*et leader. oreign partners represented in b$ this division include @odre. 3onsumer #roducts %for hair care and s*in care products(, #arle @roup %for #arle @ biscuits(, Beiersdorf, @erman$ %for 7ivea range of products( and 3olgate #almolive. A3! has formed .oint ventures )ith leading M3@ and agribusiness pla$ers in the region. These are/

D6

sian #onsumer #are 5ri<ate 9imited: Joint venture of A3! and ;edroc* Limited, for distribution of various ranges of Dabur products in Bangladesh. A3! holds >AK sta*e in the venture. Tetley #0 (angladesh 9imited: Joint venture of A3! and Tetle$ @roup of United 4ingdom for distribution of Tetle$ products in Bangladesh, )ith A3! having >AK shareholding

Man$ A3! products have crossed our national boundar$ and are being successfull$ e2ported to various countries in Asia, the Middle East and the 3!& region. The response of foreign consumers to our products has been encouraging A3! has three separate manufacturing plants in the outs*irts of Dha*a. The #harmaceuticals plant is located at 7ara$angan.I A3! ormulations has been setup at @azipur and the Tetle$ factor$ has been built at 4onabari. A3! Limited is the first compan$ in Bangladesh to have attained the !&- EAAD certification for ?ualit$ Management &$stem and !&- D=AAD for Environmental Management &$stem. The Trading subsidiar$ has also received !&- EAA6 certificate. At our manufacturing facilities, )e follo) c@M# guidelines and standards recommended b$ 1orld 8ealth -rganization %18-( for pharmaceutical formulations.

2.1.= A3! has the follo)ing subsidiaries/

A3! ormulations Ltd. Ape2 Leathercrafts Limited A3! &alt Limited A3! #ure lour Limited A3! oods Limited #remiafle2 #lastics Limited 3reative 3ommunication Limited

D9

A3! Motors Limited A3! Logistics Limited

2.1.> Di<ersification into $e" 0ndustries

A3! Limited is venturing into ne) areas of business, as part of its diversification initiatives. T)o such businesses being set up are A3! &alt Limited. and A3! @odre. Agrovet #rivate Limited.

#0 Salt 9imited: A3! has set up its salt refining plant in ;upgan., on the ban*s of the &hitala*h$a ;iver. The plant )ill produce refined iodized salt through Thermal Evaporation &$stem. A3! has used technolog$ from 3hina 8eav$ Machineries 3orporation %38M3( in establishing the plant. The end product )ill be of high 0ualit$, free"flo)ing salt )ith even, cr$stallized grains. The iodine content of A3! salt )ill have a stabilit$ of more than B months. The pro.ect has been underta*en at an appro2imate cost of Ta*a 96 crores. #0 .odre% gro<et 5ri<ate 9imited/ @odre. is a pioneer in the pac*aged meat business in !ndia. !t is also the mar*et leader in the poultr$ industr$, and the o)ner of +;eal @ood, brand. A3! and @odre. have a .oint venture in Bangladesh to set up an !ntegrated #oultr$ #ro.ect. Under this pro.ect, A3! @odre. Agrovet has alread$ set up a feed mill at &ira.gan.. This is full$ automatic pellet poultr$ and fisheries feed mill, )hich uses technolog$ from Jiangsu Mu$ang group of 3hina. The compan$ has also set up a hatcher$ at Jo$nabazar, on the Dha*a M$mensingh road, )ith technolog$ from @odre.. The plans for this pro.ect also include establishing @rand #arents and #arent &toc* breeding farms. The investment in the pro.ect is Ta*a F crores, )ith A3! Limited having >AK shareholding of the compan$.

D=

2.1.1? #0 1ormulations 9imited

A3! ormulations Limited %A3! L( is a subsidiar$ of A3! Limited, located at @azipur, in the outs*irt of Dha*a. A3! L manufactures ma.orit$ of the products of A3! &trategic Business Limited e2cept for the #harmaceutical Division. The factor$ is e0uipped )ith the state "of "the "art facilities for product formulations and process innovation. These include modern computerized e0uipment li*e 8#L3 and @L3. The product range manufactured at A3! L include 3rop #rotection 3hemicals li*e insecticides, herbicides and fungicides in granular, po)der and li0uid forms, Mos0uito #esticides in the forms of aerosols, vaporizers and coilsI and household chemicals li*e toilet cleaners and hand )ash. Quality 5olicy A3!Gs mission is to achieve business e2cellence through 0ualit$ b$ understanding, accepting, meeting and e2ceeding customer e2pectations. A3! follo)s !nternational &tandards on ?ualit$ Management &$stem to ensure consistent 0ualit$ of products and services to achieve customer satisfaction. A3! also meets all national regulator$ re0uirements relating to its current businesses and ensures that current @ood Manufacturing #ractices %c@M#( as recommended b$ 1orld 8ealth -rganization is follo)ed for its pharmaceutical operations. The management of A3! commits itself to 0ualit$ as the prime consideration in all its business decisions. All emplo$ees of A3! must follo) documented procedures to ensure compliance )ith 0ualit$ standards. The pool of human resources of the compan$ )ill be developed to their full potential and harnessed through regular training and their participation in see*ing continuous improvement of )or* methods. *$;0')$M*$T 9 5)90#@: A3! is committed to maintain the harmonious balance of our eco"s$stem and therefore constantl$ see*s )a$s to manufacture and produce products in an eco"friendl$ manner so that the balance of nature remains undisturbed and the environment remains sustainable. D>

0n pursuit of this goalA #0 "ill

3ompl$ full$ )ith all local and national environmental regulations. 3onserve natural resources li*e )ater and energ$ for sustainable development, and adopt environmentall$ safe processes.

Ensure appropriate treatment of all effluents prior to discharge, to prevent pollution or degradation of environment.

Ensure appropriate communication and cooperate )ith internal and e2ternal interested parties on environmental issues.

3reate a)areness on environmental issues among our emplo$ees and suppliers. Adopt modern )aste management technolog$.

6.D.DD 5')D!#T 5roduct 5osition: A3! formulates and mar*ets a comprehensive range of more than D6A products covering all ma.or therapeutic areas, )hich come in tablet, capsule, po)der, li0uid, cream, ointment, gel ophthalmic and in.ection forms. A3! also mar*ets )orld"reno)ned branded pharmaceutical products li*e Diprivan, luothane, 7olvade2, Accolate, Meronem, Atara2, 8umulin, 3eclor etc. from )orld"class multinational companies li*e A&T;AHE7E3A, U4I EL! L!LLL, U&A and U3B, BEL@!UM in Bangladesh. A3! #harmaceutical produces ra) materials for pharmaceutical industr$. #roducts of A3! #harmaceutical are as follo)s/ DB

3austic &oda Li0uid 3austic &oda #earl 3austic &oda &olid 3ereclor 3hlorinated #araffin 3hloroform Meth$lene 3hloride #er*lone"D %#erchloro Eth$lene( Tri*lone %Trichloro Eth$lene( Arcton DDM62 #ropafilm %B-##( M$th$l Methacr$late Monomer %MMA( #ermuthane Titanium Dio2ide %both Anatese < ;utile( ##>C66ED %Larn @rade( 8D#E %all grade( LLD#E %LLDAAD4U( LD#E %@eneral #urpose( &oda Ash %8eav$( &odium 3arbonate &$nperonic #EM "FC Terpinol B# Trisodium 3itrate Accicure MBT, MBT&, 8B&, Accelerator %;ubber 3hemicals( Atenolol B# #ropanolol 83L &pan"BA T)een BA Accimel

DC

Accino2 H3 Accitard ;E Acetone E# "&9AM=A E22"#rintTF6A Methanol 7 Butanol E22ol N$lene Europrene &B; D>A6%&t$rene Butadiene ;ubber( Europrene 8& B> %8igh &t$rene ;ubber( Butachlor %#ol$ 3hloroprene ;ubber( 8$drogen #ero2ide 9>KM>AK 7apara* %#:3 &tabilizer( Boric Acid 3ascophen% #henolic ;esin( 3itric Acid umeric Acid @ &odium Benzoate B# :egetable &tearine 3alcium 3arbonate #ol$ Eth$lene Terepthalate %#ET( #harma Bul* 3hemical 5roduct Quality: A3! #harmaceutical is al)a$s committed to serve our customer b$ understanding their needs, b$ providing technical advice and assistance and b$ ensuring timel$ deliver$. #lease call us )ith $our specialized needsMin0uir$ and are read$ to serve $ou )ith 0ualit$ products, competitive price and ensure timel$ deliver$.

DF

Man$ A3! products have crossed our national boundar$ and are being successfull$ e2ported to various countries in Asia, the Middle East and the 3!& region. The response of foreign consumers to our products has been encouraging. A3! has three separate manufacturing plants in the outs*irts of Dha*a. The #harmaceuticals plant is located at 7ara$angan.I A3! ormulations has been setup at @azipur and the Tetle$ factor$ has been built at 4onabari. A3! Limited is the first compan$ in Bangladesh to have attained the !&- EAAD certification for ?ualit$ Management &$stem and !&- D=AAD for Environmental Management &$stem. The Trading subsidiar$ has also received !&- EAA6 certificate. At our manufacturing facilities, )e follo) c@M# guidelines and standards recommended b$ 1orld 8ealth -rganization %18-( for pharmaceutical formulations. A3! follo)s !nternational &tandards on ?ualit$ Management &$stem to ensure consistent 0ualit$ of products and services to achieve customer satisfaction. A3! also meets all national regulator$ re0uirements relating to its current businesses and ensures that current +@ood Manufacturing #ractices, %c@M#( as recommended b$ 1orld 8ealth -rganization is follo)ed for its pharmaceutical operations. This dedicated team pla$s the vigilant role of controlling, ensuring and maintaining the consistent 0ualit$ of products for )hich A3! is so )ell recognized.

2.1.12 #)M5 $@ S&)T $ 9@S0S Strength #roducing also ra) materials Availabilit$ of products in domestic mar*et and rural mar*et &ea/ness ;esearch and Development rate is lo) Management team is not )ell DE

)pportunity 8ave large mar*et in rural areas Threat #olitical condition 3ompetitors are gro)ing up

2.2 S,B1 *s/ayef 5harmaceutical

2.2.1 ( #,.')!$D Es*a$ef Bangladesh Limited, a successor of &mith4line < rench in Bangladesh, is one of the countr$Gs fastest gro)ing top ten pharmaceutical companies. 1e manufacture and mar*et a )ide range of therapeutic drugs, pharmaceutical ra) materials and animal health and nutrition products. 1e are one of the members of the Transcom @roup of 3ompanies, a leading conglomerate in Bangladesh. The top management of Transcom has a long legac$ of commercial and industrial enterprise since DFFB. The )or*force of Es*a$ef consists of more than D6AA appropriatel$ 0ualified, trained and s*illed personnel )ho are dra)n from different disciplines that have a bearing on the pharmaceutical industr$. -ur team of dedicated professionals includes a panopl$ of pharmacists, medical graduates, microbiologists, chemists, engineers and business management e2perts. Their competencies, e2perience and strict adherence to the )or* ethic go into the manufacturing and mar*eting of each of the compan$Gs products. -ur Total ?ualit$ &$stem is our *e$ strength. 1e have inherited the &tandard -perating #rocedures and ?ualit$"Approach of &mith4line < rench. -ur 18- audited plants produce the products conforming to the highest international standards. And to maintain

6A

the e2cellence that )e strive to achieve )e use the most advanced technolog$ for 0ualit$ control and at each and ever$ stage of the manufacturing process. 2.2.2 ;ision 8 Mission Es*a$ef envisions a leading role for itself as a catal$st for improvement of the healthcare environment. The compan$Gs mission is to maintain peopleGs health and combat disease to enhance the 0ualit$ of human life so that people ma$ live longer, healthier and more meaningful lives.

+uman 'esources: The )or*force of Es*a$ef consists of more than D6AA appropriatel$ 0ualified, trained and s*illed personnel )ho are dra)n from different disciplines that have a bearing on the pharmaceutical industr$. -ur team of dedicated professionals includes panopl$ of pharmacists, medical graduates, microbiologists, chemists, engineers and business management e2perts. Their competencies, e2perience and strict adherence to the )or* ethic go into the manufacturing and mar*eting of each of the compan$Gs products. 1ith 0ualified, trained and s*illed professionals on its staff and its uns)erving standards of 0ualit$ control, the compan$ has distinguished itself as one of the most respected names in the pharmaceutical industr$.

2.2.5 (!S0$*SS !$0T Es*a$ef Bangladesh Ltd. started its operation )ith pharmaceutical finished products for the home mar*et. -ver time )e have diversified our operations into bul* products as )ell as animal health and nutrition products.

6D

1inished 5roducts 1e manufacture >E pharma finished products in DD6 dosage forms and mar*et them throughout Bangladesh. (ul/ 5roducts )e produce Timed ;elease Blended #ellets. Es*a$ef is the first and onl$ pellet manufacturer in Bangladesh. nimal +ealth and $utrition 5roducts 1e manufacture 6F animal health and nutrition products in >C dosage forms and mar*et them throughout Bangladesh. *:port )e mar*et our products in 7epal through e2clusive agents. 1e are in the process of establishing our presence in M$anmar, &ri Lan*a and the #hilippines. Mar/eting of 0nternational (rands )e are the sole agent in Bangladesh for mar*eting the ophthalmic products of Allergen #harmaceuticals Ltd., !reland in Bangladesh.

2.2.7 D0ST'0(!T0)$ Transcom Distri-ution #o. 9td. %TD3L( is the sole distributor of Es*a$ef products throughout Bangladesh. !t is the largest independent distribution setup in Bangladesh )ith a )ide net)or* of branch offices, )arehouses and deliver$ s$stems. -ur distribution net)or* consists of D> depots located at different strategic mar*et locations to reach more than 9A,AAA outlets throughout Bangladesh.

66

69

Depots of TD#9 %As on DC March,6AA9( Dha/a6South >6,Moti.heel 3MA Dha*a"DAAA Tel/ E>BDCCA, E>BDADD a2/ A6"E>>6==9 #hittagong DA Agrabad 3MA 3hittagang Tel/ A9D"CDB=B9 a2/A9D"CDA>EF $oa/hali 4a.i 3olon$, 1est ;a.arampur Mai.dee 3ourt, 7oa*hali Tel/ A96D"BDB99 a2/A96D"BD6C> Mymensingh B!3, M$mensingh B, Atul 3ha*robort$ ;oad M$mensingh Tel/ AED">=>CD a2/ AED">99D> (arisal B!3, Barisal &aleha 3ottege, EEMEE #olitechnic ;oad Ale*anda, Barisal Tel/ A=9D">=9F= a2/ A=9D">6CCB (ogra Jalesh)aritola Bogra To)n, Bogra TelM a2/ A>D">=EE 'angpur D6AM9 @omostapara 6= ;oad 7o. AD, ;angpur TelM a2/ A>6D"B=6=E 1aridpur Jubilitan* ;oad &outh 4alibari, Jhiltuli, aridpur Tel/ AB9D"B6FFF Sylhet #atharia #alace 7a$a &ara*, &$lhet Tel/ AF6D"CD6DFC a2/ AF6D"CDD=FE ,hulna DDB, &ir !0bal ;oad 4hulna TelM a2/ A=D"C6>EBE #omilla 6>E &hahid &hamsul 8a0 ;oad Jha)tala, 3omilla TelM a2/AFD"CB6A> Dha/a6$orth &adar ;oad, Moha*hali B6,Dha*a"D6AB @#- Bo2 TelM a2/EFEEFDD

2.2.C #ondition of 1acilities and *4uipment: The facilities and e0uipment are as follo)s/

Most stable pellets %over t)o $ears self life( Manufactured b$ using best coating materials, meth$l acr$lic acid and its co" pol$ners for sustained effect and gastro resistance.

&mooth, uniform and unchanged release profile over the entire shelf life. 7o lump formations observed during shelf life. #8 independenc$ in terms of release pattern. 7o discoloration of pellets if the pac*aging components are suitable for the product.

;egular and uniform shape increases flo) abilit$, speed of encapsulation and machine suitabilit$.

Uniform size therefore no chance of segregation.

2.2.= 5')D!#T 9ocally Manufactured 5roducts Bac*ed b$ &45 ,s strong technical and mar*eting teams )e offer D6A products in 9E therapeutic segments. ALBE7 Albendazole AMB-TE7 Ambro2ol 83L A7A#;!L Enalapril 6>

A;-3E 3efadro2il monoh$drate B;-M!D 8$oscine but$lbromide 3A;BAH!7 3arbamazepine 3A;B-L!7 3arbocisteine 3A;D-7 Losartan potassium 3A;D-#LU& Losartan potassium 5 8$drochlorothiazide 3ED7!; 3efdinir 3EL!#;E&& 3eliprolol h$drocholoride 3E L-7 3efaclor 3L-;-7 3lonazepam 3-;T!DE; 8$drocortisone acetate 3-&AT 3o"trimo2azole 3;E&T-7 ;osuvastatin DA7AMET Danazol DAL#;-N -2aprozine DEN#-TE7 De2tromethorphan 5 #seudoephedrine5 Triprolidine 83l DE&-D!7 Desloratadine DEH!DE Thiazide5Triamterene D!AL-7 @limepiride D!LAT-; Bambuterol

6B

D-;E7TA Diphenh$dramine h$drochloride EMEH!7 Meclizine h$drochloride E&-;AL Esomeprazole ET-;!N Etorico2ib EN#-TE7 @uaiphenesin5 #seudoephedrine5 Triprolidine 83l EHL 3eleco2ib EHL"; ;ofeco2ib A3!D usidic acid A3!D"83 6K fusidic acid )ith DK h$drocortisone acetate E- -L !ron 5 olic acid E- -L"3! 3arbon$l iron and folic acid LU3L-N!7 luclo2acillin LU3-DE; luconazole -L:!T !ron5 folic acid5 vitamin B"comple2 5 vitamin 3 -L:!T 3! 3arbon$l iron, folic acid, vitamin 3, vitamin B comple2 @AT!7-N @atiflo2acin @EL!3-7 @emfibrozil @LU7-; Metformin h$drochloride @LU7-; N; Metformin h$drochloride 8!"3 :itamin 3 8U77L @l$cerol < Li0uid &ucrose

6C

!;BE& !rbesartan 4ET-7!3 4etorolac tromethamine 4L7-L 4etoprofen LAM!D!7 Lamivudine LAN!T-L Lactitol monoh$drate L!#!3-7 Atorvastatin L-&E3T!L -meprazole L-&E3T!L D; TABLET -meprazole L-&E3T!L # & -meprazole LUM-7A Montelu*ast MEB!DAL Mebh$droline ME3-#E7 Mecobalamin MET3- Metronidazole M!LAM Midazolam MU#!;-7 Mupirocin ML3- !7 Terbinafine ML3- !7 3;EAM Terbinafine h$drochloride 7A#;-N 7apro2en 7E-;EN 3efale2in 7E-&AL!7E &odium chloride, potassium chloride, trisodium citrate as dih$drate and anh$drous glucose

6F

7-3L-@ 3lopidogrel 7-;!UM lunarizine -7T!7 3etirizine -;AD!7 Loratadine -radin #lus Loratadine5pseudoephedrine -&T-3AL 3alcium carbonate -&T-3AL D 3alcium 5 vitamin -&T-3AL"M 3alcium 5 Magnesium 5 Hinc 5 :itamin"D #A7-;AL #A7T-#;AH-LE #A;L-N &parflo2acin #E#T!L"8 ;anitidine #E;-&A #ermethrin #;!-3!7 Er$throm$cin #;!-:!T :it.A 5 :it.E 5 :it.3 #;-A3T!7 3$proheptadine ?U!7-N 3iproflo2acin ;E-ME7 3lomiphene citrate ;E&T-L Bromazepam ;!D-7 Domperidone ;-N!M 3efi2ime &E7&!T lupenti2ol dih$drochloride and melitracen h$drochloride

6E

&E7T!N lupenti2ol dih$drochloride &!D-#!7 Amlodipine &!D-#LU& Amlodipine and Atenolol &4"3E 3ephradine &4"M-N Amo2icillin &4"flu -seltamivir #hosphate &- T! Hinc and castor oil &-LB!-7 :itamin BD, BB < BD6 &-L:!T"M Multi vitamin )ith minerals &-L:!T"B :itamin B"comple2 &-L:!T-7E :itamin B"comple2 &TA;!7 3efpodo2ime pro2etil &T-MA Aluminium h$dro2 5 Magnesium h$dro2. &T-MA @A& Alu. h$dro2.5 Mag. h$dro2.5 &imethicone TAME7 #aracetamol TAME7"N #aracetamol and 3affeine TELAH!7E Trifluoperazine T!B& Tegaserod Maleate T-#E;!7 Tolperisone h$drochloride T-T! 4etotifen fumarate T;!JE3T 3eftria2one sodium in.ection

9A

TU

-N Aceclofenac

TUML 3alcium carbonate :E;-7 Mebeverine 83l :!73ET :inpocetine :!T;UM @-LD Multi vitamin and multi mineral :!T;UM &!L:E; Multivitamins and Multimineralsl NE7-N!7 Levoflo2acin N!73 Hinc sulphate N!73 B Hinc and vitamin B comple2 s$rup NE7T8-L 9A Meth$l salic$late 9AK < Menthol FK cream HEE -L !ron5 olic acid5Hinc HEE -L"3! 3arbon$l iron, folic acid and zinc H!L:!T Hinc,carbon$l iron, folic acid, vitamin B comple2 and vitamin 3 H!T8;-N Azithrom$cin

2.2.> 5roduct Quality: The Total ?ualit$ &$stem is &45 #harmaceutical,s *e$ strength. !t has inherited the &tandard -perating #rocedures and ?ualit$"Approach of &mith4line < rench. !ts 18audited plants produce the products conforming to the highest international standards. And to maintain the e2cellence that )e strive to achieve &45 #harmaceutical uses the most advanced technolog$ for 0ualit$ control and at each and ever$ stage of the manufacturing pro

9D

2.2.1? Mar/eting #apa-ility: Es*a$ef Bangladesh Ltd. started its operation )ith pharmaceutical finished products for the home mar*et. -ver time )e have diversified our operations into bul* products as )ell as animal health and nutrition products.

1inished 5roducts &45 #harmaceutical manufactures >E pharma"finished products in DD6 dosage forms and mar*ets them throughout Bangladesh.

(ul/ 5roducts &45 #harmaceutical produces Timed ;elease Blended #ellets. Es*a$ef is the first and onl$ pellet manufacturer in Bangladesh. nimal +ealth and $utrition 5roducts &45 #harmaceutical manufactures 6F animal health and nutrition products in >C dosage forms and mar*ets them throughout Bangladesh. *:port &45 #harmaceutical mar*ets the products in 7epal through e2clusive agents. !t is in the process of establishing &45 #harmaceutical,s presence in M$anmar, &ri Lan*a and the #hilippines.

Mar/eting of 0nternational (rands &45 #harmaceutical is the sole agent in Bangladesh for mar*eting the ophthalmic products of Allergan #harmaceuticals Ltd., !reland in Bangladesh. 2.2.11 S&)T $ 9@S0S:

96

Strength Uni0ueness of products oreign investment in production

Also produce animal drugs &ea/ness ;esearch and Development rate is lo) Management team is not )ell enough

)pportunity E2porting large amount of products Threat #olitical condition 3annot reach rural areas 3ompetitors are gro)ing up

2.3 (*D0M#) 5harmaceutical

2.3.1 #ompany )<er<ie" The histor$ of Be2imco #harma dates bac* to DECAs, )hen ;ahman brothers started to import, distribute and mar*et products sourced from )orld reno)ned companies li*e Up.ohn !nc. of the U&A and Ba$er A@ of @erman$ under sole distributor agreements.

99

B$ DEFA demand )as sufficient to .ustif$ investment in a local manufacturing facilit$. Accordingl$, the compan$ invested in a small manufacturing plant in Tongi near Dha*a, )hich )as designed and constructed )ith the technical supervision of Up.ohn !nc. The products made under licence included !ncidal and 3anesten from Ba$er and Unicap" M and Emu": from Up.ohn. B$ DEF9 Be2imco #harma had successfull$ developed its o)n generic drugs for sale in the domestic mar*et. 1ithin three $ears Be2imco #harma became the third largest local pharmaceutical compan$ in Bangladesh. Toda$ Be2imco #harma manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. Man$ of the 3ompan$Gs generic pharmaceutical products are off"patent drugs. Be2imco #harma is also permitted under the T;!#& @uidelines %the guidelines on Trade ;elated aspects of !ntellectual #ropert$ rights( to reverse engineer and sell on"patent pharmaceutical products domesticall$ and in regional mar*ets such as #a*istan, 7epal and M$anmar and in other mar*ets overseas, principall$ in East Africa %including 4en$a( and &outh East Asia %including &ingapore(. The compan$Gs t)o leading products are also the top t)o selling pharmaceutical products in Bangladesh. Be2imco #harma is also the first Bangladeshi compan$ to manufacture anti"retroviral and anti"cancer drugs. Be2imco #harma is the largest manufacturer of intra<enous fluids in Bangladesh )ith a domestic mar*et share of over => per cent. Be2imco #harma also sells intravenous fluids to ma.or medical institutions in 4en$a, #a*istan and M$anmar. Be2imco #harma also manufactures a number of acti<e pharmaceutical ingredients, or A#!s, )hich form the base of finished pharmaceutical formulations, for the 3ompan$Gs o)n use and for sale to other pharmaceutical manufacturers. These products are sold in the domestic mar*et and have also been sold in international mar*ets such as 8ong 4ong, &outh 4orea, Mala$sia and Tai)an. The 3ompan$ also underta*es contract manufacturing for @la2o&mith4line and is about to commence manufacturing for 7ovartis. The 3ompan$ operates from a 6A acre

9=

site in Dha*a )here there are a number of purpose built manufacturing plants and buildings. The site has its o)n utilit$ infrastructure to ensure ade0uate generation and distribution of po)er and )ater. The compan$ currentl$ emplo$s over DEAA staff, both in Bangladesh and abroad. Be2imco #harma is listed on the London %L&E(, Dha*a %D&E( and 3hittagong %3&E( &toc* E2changes and has over >A,AAA &hareholders. !n the $ear ended 9D December 6AA>, the business generated turnover of appro2imatel$ Ta*a 9.99 billion and profits after ta2 of appro2imatel$ Ta*a =FE.6B million.

)rgani2ational Structure: The Board of Directors, an E2ecutive 3ommittee and a Management 3ommittee team manage Be2imco #harmaceutical. DD Directors in the Board are responsible for our corporate governance. The E2ecutive 3ommittee is accountable for both operational and financial performance of the compan$. This 3ommittee is also responsible for budget approvals, polic$ adoptions or changes, ne) pro.ectsG revie)s, compliance audit etc. Management committee revie)s and manages da$"to"da$ business operations and recommends strateg$ options to the E2ecutive 3ommittee. The 3hief e2ecutive officer %3E-( is responsible for the overall management of the business.

+uman 'esources: Be2imco #harma is the pioneer in implementing corporate governance to professionall$ run a compan$ in Bangladesh. 1e believe that people invest their ideas and )or* in Be2imco #harmaI so it is our responsibilit$ to ma*e it easier and convenient for them b$ providing an environment, )hich fosters creativit$, innovation, self"development and entrepreneurship. 9>

Be2imco #harma,s human capital comprises of over EAA $oung and highl$ motivated e2ecutives )ho reflect a diversit$ of bac*ground, e2perience and perspective. The$ have sho)n their s*ills to guide our compan$ to achieve our business goal to transform this compan$ into a trul$ international one

2.3.7 5')D!#T 5roduct 5osition: The products of Be2imco #harmaceutical can be categorized based on the diseases. The products are as follo)s/ '*S50' T)'@ eronid %Budesonide 6AA mcgM actuation( 99*'.0# D0S)'D*'S ero<il %#heniramine meleate &$rup( tri2in %3etirizine 8$drochloride Tablet, &$rup, #ediatric Drops( :odin % e2ofenadine Tablet( (e:idal %Mebh$drolin Tablet( #urin %Levocetirizine Tablet( Momento %Desloratadine Tablet, &$rup( $a2olin %-2$metazoline 8$drochloride 7asal &pra$( 5edeamin %Diphenh$dramine 8$drochloride &$rup(

9B

5erinase % luticasone #ropionate 7asal &pra$( 5retin %Loratadine Tablet( 5retin D %Loratadine and #seudoephedrine Tablet( 5rome2in %#romethazine 8$drochloride &$rup( #)!.+ 8 #)9D De:tromethorphan %De2tromethorphan &$rup( Mucosol %Ambro2ol s$rup Ambro2ol Drops( $o/of %3arobcistine &$rup D& &$rup( 5rude: %De2tromethorphan, #seudoephedrine and Triprolidine &$rup( Spulyt %Bromhe2ine 8$drochloride Tablet, &$rup( Tripec %@uaifenesin #seudoephedrine < Triprolidine &$rup( D0 (*T*S #om-imet %@lipizide and Metformin Tablet( Diactin %@lipizide Tablet( Diaglit %#ioglitazone Tablet( Diapro %@liclazide Tablet( Diaryl %@limepiride Tablet( 0nformet %Metformin 8$drocloride Tablet( 5remil %;epaglinide Tablet( . ST') 0$T*ST0$ 9 Deflu: %Domperidone Dispersible Tablet, &uspensiuon < Drops( 1latameal DS %Al 8$dro2ide, Mg 8$dro2ide and &imethicone Tablet &uspension( 1rela: %#eth$lene @l$col #o)der for &uspension( 9actameal %Aluminium 8$droi2de < Magnesium Tablet, &uspension( $eoceptin ' %;anitidine Tablet, &$rup and !n.ection( $eo/it %-meprazole 3apsule, Metronidazole Tablet, 3larithrom$cin Tablet(

9C

)pton %Esomeprazole Tablet( 5anto-e: %#antoprazole Tablet( 5rotolan %Lansoprazole( 5ylopac %Lansoprazole 3apsule, Metronidazole Tablet and 3larithrom$cin Ttablet( 'ostil %Mebeverine 8$drochloride Tablet( Serelose %Lactulose oral &elution( Spanil %8$scine But$lbromide Tablet( Ta<erin %Drotaverine 8$drochloride Tablet( Derod %Tegaserod Tablet( @amadin % amotidine Tablet( 3ymet %#ancreatin Tablet( $T060$1*#T0;* ri:on %3eftria2one !: M !M in.ection( rlin %Linezolid tablet < suspension( <ifi: %7elfinavir Tablet( <ilam %Lamivudine Tablet( 2ithrocin %Azithrom$cin 3apsule Tablet < Dr$ #o)der for &uspension( #efida %3efdinir #o)der &uspension( #ephalen %3ephale2in 3apsule, &uspension( #lo-e: %3lo2acillin 3apsule &$rup( Dia<i: %Lamivudine Hidovudine Tablet( *trocin %Er$throm$cin Eth$lsuccinate Tablet, &uspension( *<o %Levoflo2acin Tablet, -ral &olution( 1ilmet %Metronidazole Tablet, &uspension, !: !nfusion( 1lu-e: % luclo2cillin 3apsule, &$rup D& &$rup( 1ungistin %7$statin &uspension( 0ntracef %3efradine 3apsule, &uspension, Drops,D& &uspention, !n.ection( 0soflo:acin %#eflo2acin Tablet( Megado: %Do2$c$cline 3apsule(

9F

Megatrim %3otrimo2azole D& tablet < &uspension( $eoflo:in %3iproflo2acin 8$drochloride film 3oated Tablet, N; film 3oated Tablet, intravenous infusion( $eosten ;T %3lotrimazole :aginal Tablet( )dycin %Mo2iflo2acin Tablet( )seflu %-seltamivir 3apsule( )<alac %:alac$clovir Tablet( Sparlin %&parflo2acin Tablet( Triocim %3efi2ime 3apsule, &uspension( Trio<i: %Lamivudine Hidovudine 7evirapine Tablet( Tycil %Amo2icillin 3apsules, &uspension( ;ercef %3efpodo2ime &uspension, Drops, D& &uspension( Degal %@atiflo2acin Tablet( Dynor %-rnidazole film coated Tablet( $ 9.*S0#8 $T05@'*T0# 9ucidol %Tramadol 3apsule( $apa %#aracetamol( S,0$ # '* (urnsil %&ilver &ulfadiazine 3ream( #osmotrin %Tretinoin 3ream( *cotrim %Econazole 7itrate and Triamcinolone Acetonide 3ream( *:o<ate $ %3lobetasol #ropionate, 7eom$cin &ulfate and 7$statin 3ream( 1urasep %7itrofurazone 3ream( 1usidic 5lus %&odium usidate and 8$drocortisone -intment( .entocep %@entamicin cream( $eosten %3lotrimazole 3ream( $osca- %#ermethrin 3ream( Q6'ash %Hinc -2ide -intment(

9E

Soritene %Tazarotene( Ter-e: %Terbinafine 8$drochloride Tablet, 3ream( ;0T M0$S $D M0$*' 9S S!559*M*$T ristocal %3alcium Tablet( ristocal D %3alcium :itamin D Tablet( ristoferon % errous sulphate Tablet( ristofol 1e % errous umarate < olic acid Tablet( risto<it (A ristople: Syrup %:itamin B comple2 Tablet( risto<it D %Anti"o2idant vitamins and mineralsTablet( risto<it6M %Multivitamin )ith mineral Tablet( sco-e: %Ascorbic Acid che)able Tablet( <itron ; %Thiamine 83l Tablet( (e:trum %Multivitamin )ith multimineral Tablet( (e:trum .old %96 multivitamin multimineral )ith complete antio2idant Tablet( #arnita- %Levocarnitine Tablet( #arocet %Beta"3arotene :itamin 3 and :itamin E Tablet( *fol *' %!ron 5 olic Acid 5 Hinc e2tended release 3apsule( 1ormula * %:itamin E Tablet( Mom<it %:itamins A, D, 3, 3alcium, #otasium, !odide Tablet( )mni<it %!ron, loic acid, Hinc, :itamin B comple2 < 3apsule( 5reg<it %!ron, olic acid, :itamin 3 < B 3omple2 3apsule( Tynisol %:itamin B 3omple2 < :itamin 3 Drops( ;itonic %!ron, :itamin B 3omple2 and Hinc &$rup( ;i<is %:itamin 3, :itamin E, Hinc, 3opper, Lutein 3apsule( 3ede: DS %Hinc &ulphate &$rup( )T+*' 5')D!#TS lendon %Alendronate &odium Tablet( nustat %3inchocaine, 8$drocortisone B#,7eom$cine sulphate U&#,Esculin ses0uih$drate -intment(

=A

#eri<in %:inpocetine Tablet( 1ertil %3lomiphene 3itrate Tablet( 5rosfin % inasteride Tablet( 'ecur % inasteride coated Tablet( Tamona %Tamo2ifen Tablet( !roflo %Tamsulosin modified release 3apsule( ;asola: %#ento2iph$lline Tablet( 3ocil %3ilostazol Tablets( 3y-e: S' %Bupropion 8$drochloride sustained release Tablet( 5roduct Quality: The name Be2imco #harma assures $ou of man$ things/ outstanding product 0ualit$, leading"edge technolog$, advanced ne) products, and a commitment to serve the medical communit$. The products come in a )ide range of dosage forms including tablets, capsules, dr$ s$rup, po)der for suspension, cream, ointment, suppositories, metered dose nasal spra$s, large volume intravenous fluids, metered dose inhalers etc. ensuring the global standard of 0ualit$.

8ealthcare professionals ma$ contact directl$ or alternativel$ the nearest Be2imco #harma Medical ;epresentatives for further information. Be2imco #harma,s countr$ regulations do not allo) pharmaceutical companies to offer medical advice or guidance to patients.

Leading drug manufacturer Be2imco #harmaceuticals Ltd %B#L( has introduced 9 ne) products for !nsomnia, ;espirator$ < Urinar$ Tract !nfections and for the prevention of Bronchospasm. The three ne) drugs namel$ S6#lonA *<o Solution and 'espira are first time launches from Be2imco #harma in Bangladesh. Be2imco #harmaceuticals Ltd also introduces -seflu- to fight against the Bird lu. Be2imco #harma also introduces ne) generation inhaler against persistent asthma + irst Time, in Bangladesh name #esonide. =D

The 0ualities of the categorized products of Be2imco #harmaceutical are as follo)s/ '*S50' T)'@ Be2imco #harma is the largest producer and supplier of Metered Dose !nhalers % MD !s( in Bangladesh. 3urrentl$ Be2imco #harma supplies around >6K of local production of MD!s in Bangladesh . !t has a )ide range of MD!s/ G;elieverG, G#reventerG and G3ontrollerG for the treatment of asthma and 3-#D. The compan$ also underta*es contract manufacturing for @la2o &mith4line for its reliever brand. ;ecentl$, B#L has launched its 3 3 free, ozone"benign 8 A metered dose inhalers, Azmasol 8 A and Decomit 8 A in the Bangladesh mar*et in technical collaboration )ith Bespa*, )orldGs leading compan$ in MD! drug deliver$ technolog$. This ma*es B#L the 6nd compan$ is Asia and Eth compan$ in the )hole )orld that manufactures 8 A based ozone benign metered dose inhalers for asthma and 3-#D. S,0$ # '* Be2imco #harmaGs robust product line in the s*in care categor$ offers eas$ and convenient solution to )ide range of s*in diseases li *e fungal and bacterial infections, eczema, atopic dermatitis, other inflammator$ s*in diseases re0uiring corticosteroid therap$, acne, psoriasis, and various other dr$ s*in problems.

;0T M0$S $D M0$*' 9S S!559*M*$T Be2imco #harmaGs man$ brands in the vitamins and nutritional supplement categor$ has gained t rust of the ph$sicians in treating various vitamins and nutritional deficienc$ s$mptoms. . ST') 0$T*ST0$ 9

=6

Be2imco #harma has a robust product line to treat diseases in the areas of gastroenterolog$. Be2imco #harmaGs 7eoceptinO";, )hich is a 86 bloc*er used in the treatment of ulcer, @E;D, and other h$peracidit$ disorders, is the number one brand in Bangladesh #harmaceutical Mar*et. Be2imco #harma )ill continue to build on its strengths in gastrointestinal categor$. D0 (*T*S Be2imco #harma offers )ide range of products ensuring effective treatment of t$pe !! diabetes. !t has the generic versions of all the leading research molecules including @lipizide, @liclazide, Metformin, @limepiride, #ioglitazone ;epaglinide etc. #)!.+ 8 #)9D 5')D!#TS 1ide product range of Be2imco #harma offers the doctors freedom to choose the right medication for different t$pes of cough/ dr$ cough, chest$ productive cough and other cough associated )ith common cold. 99*'.0# D0S)'D*'S Be2imco #harma has a strong focus to offer treatment solutions for both seasonal and perennial allergic rhinitis. The .ourne$ of Be2imco #harma in this arena began )ith the licensing arrangement )ith Ba$er A@ of @erman$ for the manufacture and mar*eting of !ncidalO in Bangladesh . #roducts in this categor$ also include a proprietar$ drug, developed b$ the ; < D team at Be2imco #harma and provides 6="hour relief of allergic rhinitis )ith congestion %mar*eted under the brand name " #retinO D( Be2imco #harma )ill continue to build on its tradition of launching the generic versions of all research molecules in this categor$. $ 9.*S0#S Be2imco #harma is the largest provider of analgesic medicines in Bangladesh, led b$ the strong performance of 7apa, a preparation of paracetamol. #aracetamol is

=9

the safest analgesic in the )orld for more than >A $ears. 7apa is the number one brand in terms of unit sales in Bangladesh and is available in D9 forms and strength. $T060$1*#T0;*S Be2imco #harma is one of the leading companies in the field of antibacterial and antiviral treatments offering a )ide range of products. The anti"infective products of Be2imco #harma are offered in different dosage forms/ Tablet, 3apsule, Large volume and &mall volume parenterals for s$stemic administration and 3ream and -intment for topical administration. Be2imco #harma is the onl$ compan$ is Bangladesh to manufacture antiviral products to treat most serious infections of 8!: %A!D&(.

2.3.C #ondition of 1acilities and *4uipment: Be2imco #harmaceutical,s manufacturing facilities are spread across a 6A acres site located in and around Dha*a, Bangladesh. The$ comprise of a number of purpose built plants, including the ne) -ral &olid Dosage %-&D( plant. The compan$ )holl$ o)ns the land and buildings and appro2imatel$ D9 of the 6A acres of land are currentl$ in use. The site includes facilities for manufacturing intravenous fluids, li0uids, creams, ointments, suppositories, metered dose inhalers, active pharmaceutical ingredients as )ell as the e2isting and ne) -&D plants for tablets and capsules, the research laborator$ and a number of )arehouses. The plant and machiner$ throughout the site has been designed, procured and installed b$ partners from @erman$, &)itzerland, &)eden, !tal$ and the United 4ingdom, amongst others. The site has its o)n utilit$ infrastructure to ensure the ade0uate generation and distribution of pure )ater at all times. The current installed electrical capacit$ is = M1 and this )ill be increased to F M1 soon. There are also )ater purif$ing and li0uid nitrogen generation facilities on site. The entire site is at least DA meters above sea level and is appro2imatel$ 6>A *ilometres from the nearest sea " the Ba$ of Bengal.

==

Be2imco #harma has al)a$s been the pioneer in adopting innovative technologies that introduced both sophistication and scale in our business processes. The focus on technolog$ is intended to ta*e our compan$ to a standard, )hich )ould match )ith other top global generic pharma companies. !t has sho)n our capabilit$ in the past b$ installing our state"of"the"art MD! plant and !: fluid plant in collaboration )ith #amasol, &)itzerland and #harmaplan, @erman$, a sister concern of resenius A@, @erman$.

!t also focuses on improving manufacturing efficienc$ to meet the challenge of maintaining the bottom line of the business in an ever"changing competitive mar*et place. 2.3.= #)M5 $@ S&)T $ 9@S0S: Strength ?ualit$ of products Availabilit$ of products in domestic mar*et ;esearch and Development rate is high &ea/ness Don,t have uni0ue products )pportunity 8ave share in foreign stoc* e2change E2porting large amount of products ;each both domestic and foreign mar*et

=>

Threat #olitical condition 3ompetitors are gro)ing up

Chapter 3

=B

%.eoretical )spects
*conomic forces Definition actors such as level of emplo$ment, rate of inflation, rate of interest, demographic changes, and fiscal and monetar$ policies, )hich determine the state of competitive environment in )hich a firm operates. These forces affect the outcome of the firmGs mar*eting activities, b$ determining the volume and strength of demand for the its products.

=C

Economics is the process b$ )hich humans manage their environment and its resources. The process is made up of a s$stem of production, distribution and consumption of goods and services. 7atural resources provide the ra) materials and energ$ for producing economic goods, )hile human resources provide the necessar$ s*ill and labor to carr$ out the process. Different societies manage their economies in different )a$s. !n a traditional econom$, people are self"sufficient %i.e., the$ produce their o)n goods(, but in a pure command econom$ the government controls all steps in the economic process. 3apitalist countries such as the United &tates have a s$stem that is largel$ based on a pure mar*et econom$. Bu$ers and sellers ma*e economic decisions based on the #rinciple of &uppl$ and Demand. &ellers suppl$ goods and bu$ers create demand for goods. These t)o roles are often in conflict/ bu$ers )ant to bu$ goods at lo) prices and sellers )ant to sell goods at high prices. 8o)ever, the t)o sides eventuall$ compromise on a price at )hich bu$ers can find sellers )illing to sell and sellers can find bu$ers )illing to bu$. This is

=F

*no)n as the mar*et e0uilibrium price. The e0uilibrium price can be considered as the intersection of the suppl$ and demand curves.

Most countries strive to increase their capacities to produce goods and services and consider doing so as a positive sign of development. Economic gro)th is stimulated b$ population gro)th, )hich in turn increases the consumption of natural resources and increases the per capita consumption of goods and services. :arious indicators are used to measure economic gro)th. -ne of them is the @ross 7ational #roduct %@7#(, )hich represents the total mar*et value of final goods and services produced b$ a countr$ during a given period %usuall$ one $ear(. Unfortunatel$, @7# does not ta*e into account the global nature of man$ companies. !f a compan$ produces goods in a foreign countr$, then the PhomeP countr$ does not reall$ benefit from that production. Thus, if #epsi bottles and sells soda in Japan, those revenues should not be included in the @7# of the United &tates. The @D# %@ross Domestic #roduct( provides a better indicator of the health of a countr$,s econom$. This measure refers to the value of the goods and services produced )ithin the boundaries of an econom$ during a given period of time.

Both the @7# and @ross Domestic #roduct %@D#( are economic measures and indicate nothing about social or environmental conditions )ithin a countr$. The$ are not measures of the 0ualit$ of life. !n fact, severe environmental problems can actuall$ raise the @7# and @D#, because the funds used to clean up environmental messes %such as hazardous )aste sites( help to create ne) .obs and increase the consumption of natural resources. The United 7ations 8uman Development !nde2 is an estimate of the 0ualit$ of life in a countr$ based on three indicators/ life e2pectanc$, literac$ rate and per capita @7#.

!/%!"*)0 'OS%S:

Economic activit$ generall$ affects the environment, usuall$ negativel$. 7atural resources are used, and large amounts of )aste are produced. These side effects can be seen as )a$s in )hich the actions of a producer impact the )ell being of a b$stander. The mar*et fails to allocate ade0uate resources to address such e2ternal costs because it is onl$ concerned )ith bu$ers and sellers, not )ith the )ell being of the environment. -nl$ direct %or internal( costs are considered relevant. E2ternal costs are harmful social or environmental effects caused b$ the production or consumption of economic goods. @overnments ma$ ta*e action to help alleviate the effects of economic activit$.

=E

1hen e2ternal costs occur, a compan$,s private production cost and the social cost of production are at odds. The firm does not consider the cost of pollution cleanup to be relevant, )hile societ$ does. The social costs of production include the negative effects of pollution and the cost of treatment. As a result, the social costs end up e2ceeding the private production costs. 1hen e2ternal pollution and treatment costs are included in the production cost of the product, the suppl$ curve intersects the demand curve at a higher price point. As a result of the higher price there )ill be less demand for the product and less pollution produced.

or e2ample, e2haust pollutants from automobiles adversel$ affect the health and )elfare of the human population. 8o)ever, oil companies consider their cost of producing gasoline to include onl$ their e2ploration and production costs. Therefore, an$ measures to reduce e2haust pollutants represent an e2ternal cost. The government tries to help reduce the problem of e2haust pollutants b$ setting emissions and fuel"efficienc$ standards for automobiles. !t also collects a gasoline ta2 that increases the final price of gasoline, )hich ma$ encourage people to drive less.

&ometimes, pollution results from the production process because no propert$ rights are involved. or e2ample, if a paper manufacturer dumps )aste in a privatel$ o)ned pond, the lando)ner generall$ ta*es legal action against the paper firm, claiming compensation for a specific loss in propert$ value caused b$ the industrial pollution. !n contrast, the air and most )ater)a$s are not o)ned b$ individuals or businesses, but instead are considered to be public goods. Because no propert$ rights are involved the generation of pollution does not affect suppl$ and demand. irms have an incentive to use public goods in the production process because doing so does not cost an$thing. !f the paper manufacturer can minimize production costs b$ dumping )astes for free into the local river then it )ill do so. The conse0uences of this pollution include adverse impacts on the fish and animal populations that depend on the )ater, degradation of the surrounding environment, decrease in the 0ualit$ of )ater used in recreation and business, human health problems and the need for e2tensive treatment of drin*ing )ater b$ do)nstream communities. An important role of the government is to protect public goods, especiall$ those )ith multiple uses, from pollution b$ companies see*ing to minimize compan$ costs and to ma2imize profits. #eople desire clean )ater for recreation and drin*ing, and the government must act to protect the broad interests of societ$ from the narro) profit"driven focus of companies.

>A

-ne )a$ to PinternalizeP some of the e2ternal costs of pollution is for the government to ta2 pollution. A pollution ta2 )ould re0uire that polluting firms pa$ a ta2 based on the air, )ater and land pollution that the$ generate. This ta2 )ould raise the private production cost of a compan$ to include to the social cost of production. !n addition, the generated ta2 revenues could be used b$ the government to help mitigate the effects of pollution. The main dra)bac* of such a ta2 is that it )ould discourage economic activit$ b$ increasing costs to the companies. or e2ample, a ta2 on coal and oil )ould increase the cost of electricit$ and gasoline. Ta2ed companies )ould be forced to scale bac* production in response to these higher costs, and investments and emplo$ment )ould suffer. The tric* is to set the ta2 at a level at )hich economic loss does not e2ceed the environmental benefits realized.

Tradable #ollution #ermits %T##s( are an alternative to pollution ta2es. !n DEE=, the United &tates government inaugurated a program to reduce sulfur dio2ide emissions b$ re0uiring that companies have a permit for each ton of sulfur dio2ide the$ emit. 3ompanies )ere allocated T##s based on their historical level of sulfur dio2ide emissions. The program allo)s T##s to be bought and sold among the companies. Therefore, a compan$ can invest in scrubbers or use more e2pensive lo) sulfur coal to reduce its sulfur dio2ide emissions and then sell its e2cess permits, offsetting part of the cost of reducing the pollution.

'OS%1,!*!$I% )*)0+S!S:

!deall$, one )ould li*e to live in a perfect )orld )ith zero pollution. Unfortunatel$, this is not possible )ith current technolog$. #eople drive cars and truc*s, and most of these vehicles have internal combustion engines, )hich emit pollutants. Unless gasoline or diesel po)ered vehicles are completel$ banned, that pollution )ill persist. 8o)ever, a fe) electric vehicles are starting to appear on the road, although the$ are impractical for long distance use or heav$ hauling. -bviousl$, most people are not going to give up their internal combustion engine vehicles in the near future. #eople generall$ accept that some pollution is a result of living in a modern societ$. The critical issue, then, is ho) much

>D

pollution control is economicall$ practical. A cost"benefit anal$sis provides an estimate of the most economicall$ efficient level of pollution reduction that is practical.

A cost"benefit anal$sis loo*s at the social benefits %e.g., health and environmental benefits( that can be derived from pollution reduction versus the cost of achieving that reduction. As the pollution reduction increases, so does the mone$ re0uired to reduce pollution further. !t ma$ not be ver$ e2pensive to clean up the bul* of most pollutants. 8o)ever, as the reduction in pollutants approaches DAA percent %i.e., zero emissions(, the marginal cost of each additional unit of pollution reduction rises dramaticall$. !f public funds are used for pollution control, there is a limit to ho) much mone$ can be spent before the budgets of other important public services %e.g., police, fire and par*s departments( are negativel$ impacted. A balance must therefore be found bet)een the social benefits of pollution reduction and the cost of pollution reduction. The proper balance bet)een costs and benefits represents the optimum economic level of pollution reduction.

The optimum level is not static, but can change as circumstances change. As technolog$ improves over time, the cost of pollution reduction ma$ decrease. Li*e)ise, as the hazards of pollution become better *no)n, the perceived benefits to be derived from pollution reduction ma$ also increase. !n either case, the optimum level of pollution reduction )ill then increase and a greater level of pollution reduction )ill be considered economicall$ feasible. The eco"efficienc$ program at the 9M 3orporation is an e2ample of ho) the optimum level of pollution reduction can be raised through better management and design of manufacturing processes. -ver the time period DEEA to 6AAA, the compan$ reduced its air pollution b$ FF percent, )ater pollution b$ F6 percent and )aste generation b$ 9> percent. -ne problem )ith using cost"benefit anal$ses for determining the optimum level of pollution reduction is that it assumes all benefits can be labeled )ith a price tag. 8o)ever, aesthetic benefits from pollution reduction cannot be priced, and $et the$ are .ust as important as others. The beaut$ of a clear"running stream and the 0uiet solitude of a )ilderness area cannot be measured in dollars and cents.

>6

Chapter 4

)nalysis 2 $indings
>9

Based on the 0uestionnaire )e have anal$zed the data and for each 0uestion )e have found the follo)ing results/ Question 1: -ur first 0uestion )as +0s pharmaceutical industry contri-uting in the countryEs economyF, rom our selected 9A samples, F samples have ans)ered +LE&,, C samples have ans)ered +&-MET!ME&, and D> samples have ans)ered +7-,. These can be sho)n into the follo)ing table/

Answer Number

Total Patients

Number of Patients

% Of the Numbers

30

26.70%

30

23.30%

30

!0%

>=

Question 2: -ur second 0uestion )as +0s pharmaceutical industry control "hole drug mar/etF, rom our selected 9A samples, > samples s have ans)ered +LE&,, F samples have ans)ered +&-MET!ME&, and DC samples have ans)ered +7-,. These can be sho)n into the follo)ing table/

Answer Number

Total Patients

Number of Patients

% Of the Numbers

30

6.70%

30

26.70%

30

!6.60%

>>

Question 3: -ur third 0uestion )as + re the drugs e:pensi<e in our countryF , rom our selected 9A samples, B samples have ans)ered +LE&,, D= samples have ans)ered +&-MET!ME&, and DA samples have ans)ered +7-,. These can be sho)n into the follo)ing table/

Answer Number

Total Patients

Number of Patients

% Of the Numbers

30

20%

30

"

"6.67%

30

33.33%

>B

Question 4: -ur fourth 0uestion )as +#an 5harmaceutical industry meet up our internal medicine demandF, rom our selected 9A samples, DA samples have ans)ered +LE&,, D> samples have ans)ered +&-MET!ME&, and > samples have ans)ered +7-,. These can be sho)n into the follo)ing table/

Answer Number

Total Patients

Number of Patients

% Of the Numbers

30

33.33%

30

!0%

30

6.67%

>C

Question

-ur fifth 0uestion )as +0s pharmaceutical industry remo<ing unemploymentF, rom our selected 9A samples, DA samples have ans)ered +LE&,, D6 samples have ans)ered +&-MET!ME&, and F samples have ans)ered +7-,. These can be sho)n into the follo)ing table/

5:

Answer Number

Total Patients

Number of Patients

% Of the Numbers

30

33.33%

30

"0%

30

26.67%

>F

Question 7: -ur si2th 0uestion )as + re 5harmaceutical companies e:panding their -usiness in "orld 6"ideF, rom our selected 9A samples, 6A samples have ans)ered +LE&,, > samples have ans)ered +&-MET!ME&, and > samples have ans)ered +7-,. These can be sho)n into the follo)ing table/

Answer Number

Total Patients

Number of Patients

% Of the Numbers

30

20

66.66%

30

6.67%

30

6.67%

>E

Question C: -ur seventh 0uestion )as +0s 5harmaceutical industry plays a <ital role in our economyF, rom our selected 9A samples, DF samples have ans)ered +LE&,, C samples have ans)ered +&-MET!ME&, and > samples have ans)ered +7-,. &o, as ans)er of ma.orit$ patients, )e can sa$ that the doctors and staffs of the healthcare organization )ant e2tra mone$ for their service. These can be sho)n into the follo)ing table/

Answer Number

Total Patients

Number of Patients

% Of the Numbers

30

60%

30

23.33%

30

6.67%

BA

Question =: -ur last 0uestion )as +Do you /no" some leading pharmaceutical companies nameF, rom our selected 9A samples, C samples have ans)ered +LE&,, DA samples have ans)ered +&-MET!ME&, and D9 samples have ans)ered +7-,. These can be sho)n into the follo)ing table/

Answer Number

Total Patients

Number of Patients

% Of the Numbers

30

23.33%

30

33.33%

30

"3.3"%

BD

Chapter 5

B6

(a3or $indings
!n Bangladesh #harmaceutical sector is one of the most developed hi tech sector, )hich is contributing in the countr$Gs econom$. The countr$Gs pharmaceutical industr$ is the largest among the least developed countries %LD3s( and gro)ing at DA per cent annuall$. Bangladesh no) produces more than >,AAA registered brands )ith the over F,AAA different dosages in different forms and strengths. The industr$,s mar*et share stood at U&Q >AA million last $ear meeting EB per cent of domestic demand in addition to e2porting to over BA counties.

#)M5*T0T0;* $ 9@S0S:
To anal$sis the competitiveness of #harmaceutical industr$, )e have to anal$sis the #harmaceutical industr$ structure and individual competitor.

0ndi<idual #ompetitor:
The #harmaceutical industr$ is no) too competitive. Man$ #harmaceutical companies are no) gro)ing up. oreign investors are investing in #harmaceutical industr$ as it has become a profitable sector in our countr$. &o, competition is building up in this sector. The competitors of #harmaceutical industr$ in Bangladesh are BEN!M3#harmaceutical, A3! #harmaceutical, &45 #harmaceutical, A3ME #harmaceutical, etc.

B9

The strength of our #harmaceutical industr$ in Bangladesh is 0ualit$ of products and the )ea*ness is lo)er technological support. The opportunit$ of #harmaceutical industr$ in Bangladesh is foreign investment and threat is our political condition.

0ndustry Structure:
A pharmaceutical compan$ is made up of a number of functions. Each function has responsibilit$ for one area of the compan$Gs activities. 8o)ever, the functions are closel$ lin*ed and it is the relationships bet)een them that help ma*e a compan$ successful. The
diagram below shows the main functions of a pharmaceutical company with the links between them. You can see more detail about the role of each function by rolling your cursor over the blue dots.

B=

Chapter 6

B>

"ecommendation
Recommendation:
Drug discover$ and development is ver$ e2pensiveI of all compounds investigated for use in humans onl$ a small fraction are eventuall$ approved in most nations b$ government appointed medical institutions or boards, )ho have to approve ne) drugs before the$ can be mar*eted in those countries. Each $ear, onl$ about 6> trul$ novel drugs %7e) chemical entities( are approved for mar*eting. This approval comes onl$ after heav$ investment in pre"clinical development and clinical trials, as )ell as a commitment to ongoing safet$ monitoring. Drugs )hich fail part")a$ through this process often incur large costs, )hile generating no revenue in return. !f the cost of these failed drugs is ta*en into account, the cost of developing a successful ne) drug %7e) chemical entit$ or 73E(, has been estimated at about D billion U&D %not including mar*eting e2penses(. A stud$ b$ the consulting firm Bain < 3ompan$ reported that the cost for discovering, developing and launching %)hich factored in mar*eting and other business e2penses( a ne) drug %along )ith the prospective drugs that fail( rose over a five $ear period to nearl$ QD.C billion in 6AA9. These estimates also ta*e into account the opportunit$ cost of investing capital man$ $ears before revenues are realized %see Time"value of mone$(. Because of the ver$ long time needed for discover$, development, and approval of pharmaceuticals, these costs can accumulate to nearl$ half the total e2pense. &ome approved drugs, such as those based on re"formulation of an e2isting active ingredient %also referred to as Line" e2tensions( are much less e2pensive to develop.

BB

3alculations and claims in this area are controversial because of the implications for regulation and subsidization of the industr$ through federall$ funded research grants. R !t is important in drug formulation.

Chapter 7

BC

'onclusion
#)$#9!S0)$ The e2port items cover )ide range of products of all ma.or therapeutic classes and dosage forms. !t includes high"technolog$ products li*e inhalers, suppositories, nasal spra$s, in.ectibles and infusions. More than D>A companies are producing drugs in the countr$ but the ver$ basic problem is that the manufacturers are still dependent on FA percent imported ra) materials. But initiatives are in place no) to set up ne) industries to produce ra) materials and the countr$Gs pharmaceutical sector )ill see a further fillip once these factories )ill start deliver$. The pharmaceutical industr$ here largel$ dominated b$

domestic producers, e2cept a fe) locall$ based multinational firms engaging in the production and mar*eting. 1e have to ma*e that the 0ualit$ and effectiveness of Bangladeshi drugs are )idel$ acclaimed in the global mar*et.

BF

Chapter 8

BE

,i4liograp.y
"eferences ,oo-:

D. #hilip 4otller, SMar*eting ManagementT D6th edition. 6. #hilip 4otllerI +#rinciples of Mar*eting, D6th Edition.

5 "eports:

D. A3! #harmaceutical Limited. 6. Be2imco #harmaceutical Limited. 9. &45 #harmaceutical Limited.

'eb Site:
. ))).google.com

6. ))).)i*ipedia.com

CA

Chapter 9

CD

)nne6ure
Questionnaire

Dear ;espondents, 1e are the students of BBA #rogram in Bangladesh Universit$ of Business < Technolog$ %BUBT(. or the potential fulfillment of the course entitled G,usiness !n7ironmentGA )e have to prepare a report on GP.armaceutical Industry is contri4uting our economyH. &o that, some information )ould be needed from $ou. !t is assured that all the information )ill *eep confidential and safel$ use in this report onl$. 5lease read carefully the 4uestions and %ust put a tic/ IJK in the respecti<e num-er and /indly gi<e your response "here necessary.

Date of !ntervie)/ M M $ame of the 'espondent: LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL 5hone M Mo-ile $o.: LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL )ffice !se )nly Serial $o/

Personal Information: 1. Se:: 2. ge: D. Male Lears 6. emale

&EN A@E

C6

8uestions "elated to Su43ect: 1. 0s pharmaceutical industry contri-uting in the countryEs economyF LE& &-MET!ME& 7L& &T 7-

2. 0s pharmaceutical industry control hole drug mar/etF LE& 3. &-MET!ME& 7-

re the drugs e:pensi<e in our countryF &-MET!ME& 7-

LE&

4. #an 5harmaceutical industry meet up our internal medicine demandF LE& &-MET!ME& 7-

5. 0s pharmaceutical industry remo<ing unemploymentF LE& 7. &-MET!ME& 7-

re 5harmaceutical companies e:panding their -usiness in "orld 6"ideF

LE&

&-MET!ME&

7-

C. 0s 5harmaceutical industry plays a <ital role in our economyF LE& &-MET!ME& 7-

=. Do you /no" some leading pharmaceutical companies nameF LE& &-MET!ME& 7-

Signature of the 'espondent UUUUUUUUUUUUUUUUUUUUUUUUU Date/ UUUUUUUUUUUUUUUUUUUUU

Signature of the 0nter<ie"er UUUUUUUUUUUUUUUUUUUUUUUUU

C9

Graphical Representation:

C=

C>

CB